Alzheon returns, with a $47 million NIH grant and one last shot at a pivotal PhIII Alzheimer’s success

Alzheon has spent four years searching for investors, public or private, willing to back a large study for their once-failed Alzheimer’s drug. On Thursday, they finally found a benefactor.